Print Options
PrintThe Whole
Directive
PrintThe Whole
Annex
PrintThe Whole
Division
PrintThis
Division
only
Changes over time for: Division
2.3.
Timeline of Changes
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
Status:
EU Directives are published on this site to aid cross referencing from UK legislation. Since IP completion day (31 December 2020 11.00 p.m.) no amendments have been applied to this version.
[ [ [2.3. Complement fixation test (CFT) U.K.
2.3.1. The antigen represents a bacterial suspension in phenol-saline (NaCl 0,85 % (m/v) and phenol at 0,5 % (v/v)) or in a veronal buffer. Antigens may be delivered in the concentrated state provided the dilution factor to be used is indicated on the bottle label. The antigen must be stored at 4 °C and not frozen. U.K.
2.3.2. Serums must be inactivated as follows: U.K.
2.3.3. In order to carry out the genuine reaction within the test procedure, a complement dose higher than the minimum necessary for total haemolysis shall be used. U.K.
2.3.4. In carrying out the complement fixation test, the following controls must be made each time: U.K.
(a)
control of the anti-complementary effect of the serum;
(b)
control of the antigen;
(c)
control of sensitised red blood cells;
(d)
control of the complement;
(e)
control using a positive serum of sensitivity at the start of the reaction;
(f)
control of the specificity of the reaction using a negative serum.
2.3.5. Calculation of results U.K.
The OIEISS contains 1 000 international CFT units (ICFTU) per ml. If the OIEISS is tested in a given method the result is given as a titre (i.e. highest direct dilution of the OIEISS giving 50 % haemolysis, T OIEISS ). The test result for the test serum given as titre (T TESTSERUM ) must be expressed in ICFTU per ml. In order to convert the expression of a titre into ICFTU, the factor (F) necessary to convert a titre of an unknown test serum (T TESTSERUM ) tested by that method into the ICFTU expression can be found from the formula:
F = 1 000 × 1/T OIEISS
and the content of international CFT units per ml of test serum (ICFTU TESTSERUM ) from the formula:
ICFTU TESTSERUM = F × T TESTSERUM
2.3.6. Interpretation of results U.K.
A serum containing 20 or more ICFTU per ml shall be considered to be positive.] ] ]
Back to top